Asia-Pacific Gene Therapy Market - 2024-2031

Overview

The Asia-Pacific gene therapy market reached US$ 0.81 billion in 2023 and is expected to reach US$ 7.97 billion by 2031, growing at a CAGR of 33.26% during the forecast period 2024-2031.

Gene therapy is a novel medical treatment that involves changing, removing, or inserting genetic material into a patient's genome to address an ailment. It shows potential as a treatment for cancer, cystic fibrosis, heart disease, diabetes, hemophilia, and HIV.

Gene therapy is in high demand with the rising genetic diseases, mostly due to the increasing incidence of different types of cancers. For instance, according to the report by the National Breast Cancer Foundation Inc., in 2024, in the United States, 1 out of 8 women will be diagnosed with breast cancer during their lifetime. In 2024, an estimated 310,720 women will be diagnosed with invasive breast carcinoma.

Market Dynamics: Drivers & Restraints

Rising funding and investments by the government and companies for gene therapy research

Rising funding and investments are expected to the market expansion. Governments are raising funds to set up research centers particularly gene therapy to treat several rare diseases as well as chronic diseases such as cancer, cardiovascular diseases, and others. Rising investments by the companies to expand their businesses by launching their operations in different parts of the region are also expected to drive the gene therapy market growth.

For instance, on April 4, 2024, The President of India, Smt Droupadi Murmu launched India's first home-grown gene therapy for cancer at IIT Bombay. As this line of treatment, named "CAR-T cell therapy", is accessible and affordable, it provides new hope for the whole of humankind. She expressed confidence that it will be successful in giving new lives to countless patients.

High developmental and treatment costs

The High developmental and treatment costs of gene therapies are expected to hinder the gene therapy market growth. Despite potential health benefits, the high costs of cell and gene therapies are expected to reduce the adoption of these procedures. In developing countries in Asia-Pacific, it is difficult for many individuals to get treated using gene therapy.

Gene therapies often come with exorbitant price tags, typically ranging from USD 300,000 to USD 4 million per patient, depending on the specific treatment and condition being addressed. For instance, the gene therapy Zolgensma, which treats spinal muscular atrophy, is priced at approximately USD 2.1 million per patient. Such high costs pose significant challenges for healthcare providers, especially smaller employers and Medicaid programs, leading to increased insurance premiums and limiting access for many patients

Segment Analysis

The Asia-Pacific gene therapy market is segmented based on approach, vector type, technique, application and region.

Vector Type:

Retrovirus segment is expected to dominate the Gene Therapy market share

The retrovirus segment is expected to dominate the gene therapy market share. Retroviral vectors are now the most often used form of gene transfer in humans. Most of the clinical trials use vectors based on amphotropic murine retroviruses. The most significant advantage of retroviral vectors is their ability to convert their single-stranded RNA genome into a double-stranded DNA molecule that stably integrates into the target cell genome. This indicates that retroviral vectors can permanently change the host cell's nuclear genome.

Retroviral vectors can be used to transfer genes to the proper cell types, such as CD4-positive T cells, which are infection targets, or progenitor cells, such as hematopoietic stem cells, which give rise to T cells.

Lentivirus segment is the fastest growing segment in the gene therapy market share

The lentivirus segment is the fastest growing segment in the gene therapy market. This is due to their growing applications in treating different conditions by incorporating them into the genome. Lentiviral vectors are a common vector for CNS gene therapy because they cause long-term gene expression within neurons while causing a minimal host immune response. These can infect both dividing and non-dividing cells, enabling long-term transgene expression in a variety of cell types, including inactive or differentiated cells. Thus, there is a growing research and development of new gene therapies using lentivirus as vectors. These factors are growing the segment's growth.

Application:

Oncology segment is expected to dominate the gene therapy market share

The Oncology segment holds a significant position in the global gene therapy market and is expected to be the dominant segment in the market. This is due to the rising investments in developing new therapies with the rising incidence of cancers. Biopharmaceutical companies and research institutes are majorly focusing on developing innovative therapies to treat various types of cancers.

To treat cancers different types of gene therapies are being used. There is an increasing number of FDA approvals for cancer gene therapies which is contributing to the market growth. For instance, on August 2, 2024, the FDA granted accelerated approval to afamitresgene autoleucel (TECELRA, Adaptimmune, LLC), a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy, for adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy.

Blood Disorders segment is the fastest growing segment in the gene therapy market share

The blood disorders segment is expected to be the fastest growing segment in the gene therapy market growth. There is a growing approach to treating various blood disorders including sickle cell disease, thalassemia and others through advanced gene therapies. Growing research and innovation of new gene therapy options to treat is expected to drive the segment's growth.

Geographical Analysis

India is expected to hold a significant position in the Gene Therapy market share

India is expected to hold a dominant share of the Asia-Pacific Gene Therapy Medicine Market. This is due to the rising demand for gene therapies in the country, and the growing prevalence of chronic and genetic disorders in the country.

Increasing research and advancements in treatment and therapeutics are also considered one of significant factors for the market growth in the country. For instance, in April 2024, India unveiled its first indigenously developed CAR T-cell therapy for cancer treatment, acknowledging it as a tremendous breakthrough that brings "new hope for humankind" in the fight against the disease. Developed by the Indian Institute of Technology (IIT) Bombay and Tata Memorial Centre, the gene-based therapy is being pushed out in India at approximately one-tenth of its price outside the country.

Japan is growing at the fastest pace in the gene therapy market

Japan is at the fastest growing pace in the gene therapy market. This is due to the growing advancements, the presence of strong regulatory support and the growing focus on research and development of new therapies. The presence of a large number of research institutes and the rising investments by government organizations in the country are also the major factors for the country's market growth.

Competitive Landscape

The major players in the Gene Therapy market include Novartis AG, Ferring Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, CSL Behring LLC, Amgen, Inc., Orchard Therapeutics plc, Krystal Biotech, Inc., Spark Therapeutics, Inc., bluebird bio, Inc., and Sarepta Therapeutics, Inc. among others.

Key Developments

• In April 2024, Pfizer Inc. received FDA approval for BEQVEZ (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var) capsid as detected by an FDA-approved test.
• In June 2024, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.

Why Purchase the Report?

• To visualize the Asia-Pacific gene therapy market segmentation based on approach, vector type, technique, application, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of gene therapy market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Asia-Pacific gene therapy market report would provide approximately 53 tables, 47 figures, and 176 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies